Small Chemicals
Market Cap
₹2,507 ₹2,507 Cr.
P/E
16.64
PEG
0.76
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis becomes actionable as Dahej and Unitop utilization ramps and high-margin pharma and premix customer conversions materialize.- The bull path depends on faster capacity utilization and richer product mix, while the bear path reflects under-utilization, export realization pressure and delayed customer approvals.

  • Rossari Biotech
  • SH Kelkar & Company
  • Oriental Aromatics

FAQs on Rossari Biotech Ltd. Shareprice

Rossari Biotech has given lower returns compared to its competitors.
Rossari Biotech has grown at ~-18.66% over the last 5yrs while peers have grown at a median rate of -6.77%

Rossari Biotech is not expensive.
Latest PE of Rossari Biotech is 16.71, while 3 year average PE is 34.34.
Also latest EV/EBITDA of Rossari Biotech is 9.49 while 3yr average is 17.5.

Growth Table

  • Rossari Biotech Ltd.
  • SH Kelkar & Company
  • Oriental Aromatics

Balance Sheet

  • Rossari Biotech Ltd.
  • SH Kelkar & Company
  • Oriental Aromatics

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Rossari Biotech Ltd.
  • SH Kelkar & Company
  • Oriental Aromatics

Cash Flow

  • Rossari Biotech Ltd.
  • SH Kelkar & Company
  • Oriental Aromatics

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Rossari Biotech Ltd.
  • SH Kelkar & Company
  • Oriental Aromatics

Quarterly Results

  • Rossari Biotech Ltd.
  • SH Kelkar & Company
  • Oriental Aromatics

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Rossari Biotech Ltd. Financials

Balance sheet of Rossari Biotech is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Rossari Biotech is increasing.
Latest net debt of Rossari Biotech is ₹224 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹74.55 Crs.

Yes, profit is increasing.
The profit of Rossari Biotech is ₹149 Crs for TTM, ₹149 Crs for Mar 2026 and ₹136 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Rossari Biotech latest dividend payout ratio is 1.86% and 3yr average dividend payout ratio is 2.0%

Companies resources are allocated to majorly productive assets like Plant & Machinery

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech